Fig 1.
Representative immunostaining of CD8, CD68, and CD169.
Tumor infiltrating CD8+ lymphocytes were evaluated in primary cancer tissues, while CD68+ and CD169+ sinus macrophages were evaluated in RLNs (A). Representative images of CD8 (B) and of CD68 and CD169 (C) immunostaining. HE, Hematoxylin-Eosin staining.
Fig 2.
Statistical analysis of associations of sinus macrophages with clinicopathological factors.
Analysis of the association of CD169+ macrophage density and the CD169+/CD68+ macrophage ratio with LN metastasis (A), clinical stage (B), the Ki-67 index (C) and prognosis (D). The Mann-Whitney U test and Kruskal-Wallis tests were performed to examine the prognostic value of CD169 in (D).
Table 1.
Association of CD169+, CD68+, and CD8+expressing cells with clinicopathological parameters in the invasive breast cancer cohort.
Table 2.
Univariate and multivariate analysis of factors for relapse-free survival.
Table 3.
Univariate and multivariate analysis of factors for distant relapse-free survival.
Table 4.
Univariate and multivariate analysis of factors for breast cancer-specific survival.
Fig 3.
Statistical analysis of associations of CD8+ lymphocytes with CD169+ macrophages and clinicopathological factors.
Analysis of the association of CD8+ lymphocyte density with CD169+ macrophage density (upper) and the CD169+/CD68+ macrophage ratio (lower) (A) and with LN metastasis (B) in all cases. Similar analyses to (A) and (B) that were performed in cases with a high Ki-67 index (>40%) are shown in (C) and (D), respectively.